idc btig estim compani document
million except per share amount
anoth tavr-if result construct view opportun
unchang valuat keep us sidelin maintain neutral
tavr result impress eclips
investor fear head print underli tavr growth solid vs
buoy robust growth low-risk expans
continu gift keep give number center addit
quarter particularli strike site total vs center
estim manag decemb analyst day manag also
indic procedur growth came across risk level ou penetr
japan momentum thank stock quarter ncd chang
continu provid foundat support busi blemish result
howev three-cent ep miss compani incur one-tim
manufacturing-rel cost acceler invest drive market adopt
remain focus sign meaning oper leverag think
investor may forgiv slippag light sale momentum
solid print optimist outlook help share recov
recent loss continu expect solid tavr beat low-risk adopt
center expans advanc tricuspid replac portfolio
via fda recent approv evoqu feasibl studi step right
direct howev share trade nearli ntm ep estim
challeng justifi premium valuat core tavr opportun
still modest contribut mitral maintain neutral rate
strateg updat post-analyst day trial track enrol
mitral sale total fall short consensu forecast
surpris us given pascal guid sheath recal mid-novemb
posit new site activ drive recoveri respect
mitral replac manag track begin enrol
though detail trial design/s yet disclos
oper margin light besid one-tim cost eu-rel regulatori
spend hurt gross margin line increment spend clinic
personnel invest diseas awar also pressur oper
metric trim oper margin forecast accordingli
expect manag opportunist pull forward
invest educ awar
valuat share trade ntm ep estim view risk-reward
balanc gain comfort compani success
mitral space maintain neutral rate risk page
edward rate neutral view edward well-round aortic mitral tricuspid portfolio
make competit long-term confid trans-sept mitral replac product
could closer previous estim howev feel share market cap price mani thing
go right bake success mitral program
advanc mitral tricuspid portfolio
maintain share tavr market
continu center adopt stabl price
mitral program materi earlier expect
top-lin growth deceler competit eu intensifi
slowdown center adopt
delay mitral program
edward lead manufactur
transcathet surgic heart
valv product repair diseas
aortic valv addit
hospit use lastli edward
well-round portfolio mitral
tricuspid therapi
develop repair
consolid revenu outperform forecast better tavr sale specif ww tavr
tmtt revenu came estim underli tavr growth better
growth seen growth compani longer break vs ou tavr perform
dollar manag estim tavr procedur grew y/i basi ew growth in-lin
market ou tavr procedur grew high-teen y/i basi ew perform also compar
 edward observ growth broad-bas similar improv high low volum center
low-risk adopt continu drive above-averag procedur growth manag saw growth across risk level
turn mitral report sale quarter consensu conserv forecast
surgic valv perform weaker expect vs tavr procedur ate savr share
quarter critic sale came forecast driven healthi demand hemospher
momentum smart recoveri
adj gross margin sequenti model quarterli weak caus
one-tim cost migrat cardioband product israel ireland invest support new european
medic devic regul adj sg margin wors forecast dollar basi sg
spend increas y/i due expans tavr clinic personnel mitral support europ
well invest diseas awar therapi adopt meanwhil adj margin better
forecast adj ebit margin dip sequenti fall short estim net-net
adjust ep came consensu forecast
actualsbtig estimate variancethv revenu revenu tmtt revenu heart valv revenu million adj consign revenu revenu expens expens net dilut gross margin bpssg margin bpsr spend bpsadj ebit margin bpstax rate bpssourc btig research estim compani filingsal metric present herein non-gaap basi margin estim non-gaap basi varianc
revenu increas estim flow beat howev lower ebit margin
higher sg adj ep forecast howev remain
edward rate neutral feel ew current market capit price lead market share
fulli penetr matur tavr market year signific mitral sale btig provid price target
neutral-r stock risk includ competit patent litig slippag product timelin chang procedur
reimburs futur devic data fda possibl multipl contraction/expans
exhibit comp tabl larg cap med-tech compani
newnewold growth incom growth btig research estim compani filingsntm johnsonjnjnot pt bdxnot scientificbsxbuy lifesciencesewneutr factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/sal
edward incom revenu inc thv return y/i good gross sg other- total oper oper incom ex interest interest expens pre-tax incom tax non-gaap net non-gaap share ex marginsgross net total total total oper tax ep btig estim compani report
edward gaap revenu us y/i ou y/i y/i broken y/i tmtt y/i heart valv y/i y/i gaap net y/i non-gaap revenu us y/i ou y/i y/i broken y/i tmtt y/i heart valv y/i y/i non-gaap net y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
